Stocks · News reference
Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, today announced the promotion of Nick Smith to president and chief
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Alto Neuroscience (NYSE:ANRO) with a Buy and raises the price target from $50 to $55.
Read original at benzingaWedbush analyst Laura Chico maintains Alto Neuroscience (NYSE:ANRO) with a Neutral and raises the price target from $24 to $26.
Read original at benzingaBTIG analyst Thomas Shrader maintains Alto Neuroscience (NYSE:ANRO) with a Buy and raises the price target from $28 to $37.
Read original at benzinga